Vantas

Orion has launched Vantas (histrelin) for the palliative treatment of advanced prostate cancer.

Vantas (histrelin) is a depot formulation of a luteinising-hormone releasing hormone (LHRH) analogue. Inserted subcutaneously into the upper arm, the implant delivers an average of 50 micrograms of histrelin acetate daily for 12 months. Histrelin inhibits LH secretion leading to a fall in circulating testosterone levels promoting tumour regression and symptom improvement.

Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely monitored for exacerbation of symptoms during the first few weeks after Vantas implantation.

View Vantas drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases